MedTrace Logo

Titanium-prepared Platelet-rich Fibrin for Treatment of Gingival Recession Using the VISTA Technique

NCT07591142 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-15

No results posted yet for this study

Summary

This split-mouth randomized clinical trial aims to compare the effectiveness of titanium-prepared platelet-rich fibrin (T-PRF) and connective tissue graft (CTG) in the treatment of Miller Class I and II gingival recession using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique. Twenty systemically healthy adult participants with bilateral gingival recession defects will receive both interventions, with one side randomly assigned to T-PRF and the contralateral side assigned to CTG. Clinical outcomes including recession depth, attached gingival width, probing depth, relative attachment level, healing, and patient satisfaction will be evaluated over a 6-month follow-up period.

Conditions

  • Gingival Diseases
  • Gingival Recession

Interventions

PROCEDURE

Titanium-Prepared Platelet-Rich Fibrin (T-PRF) with VISTA Technique

The gingival recession defects assigned to the test group will be treated using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique combined with titanium-prepared platelet-rich fibrin (T-PRF). T-PRF membranes will be prepared from the participant's autologous venous blood collected in titanium tubes and centrifuged according to a standardized protocol before placement beneath the tunneled flap.

PROCEDURE

Connective Tissue Graft (CTG) with VISTA Technique

The gingival recession defects assigned to the control group will be treated using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique combined with an autogenous connective tissue graft (CTG). The graft will be harvested from the palatal donor site and positioned beneath the tunneled gingival tissue to achieve root coverage and soft tissue augmentation.

Sponsors & Collaborators

  • Damascus University

    collaborator OTHER

  • Arab International University

    lead OTHER

Principal Investigators

  • Rania Daadoush, DDs · Damascus University

  • Tarek Qasem, PhD · Damascus University

  • Saleh Al Kurdi, PhD · Arab International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2026-01-12
Completion
2026-04-25

Countries

  • Syria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07591142 on ClinicalTrials.gov